This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Nuvance

Amgen, Inc.

Drug Names(s): Soluble IL-4 Receptor

Description: Recombinant soluble IL-4 receptors were developed by Immunex in the 1980s. In the early 1990s, cytokine research yielded preliminary preclinical results indicating that recombinant soluble receptors can interfere with the biological functions of cytokines. Despite the early promise of experimental cytokine activity modulation, trial results have not been positive, and development of Nuvance has been suspended.


Nuvance News

Pink Sheet Trademark Review


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug